Teva Pharma (TEVA) Tops Q4 EPS by 17c, FY18 Guidance Falls Short of Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Teva Reports 2017 Full Year and Fourth Quarter Financial Results
February 8, 2018 7:01 AM ESTJERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today reported results for the year and the quarter ended December 31, 2017.
 ÂFY 2017
Q4 2017
Revenues $22.4 billion $5.5 billion Cash flow from operations $3.5 billion $1.2 billion GAAP earnings (loss) per share... More